Augmentin 875mg is a high‑strength formulation of amoxicillin combined with clavulanate, designed for managing severe or recurrent bacterial infections where broader beta‑lactam coverage is required. By inhibiting bacterial cell‑wall synthesis and protecting amoxicillin from enzymatic degradation, this dosage delivers robust activity against respiratory, ENT, skin, and bite‑related pathogens. It is commonly selected for difficult cases of sinusitis, pneumonia, acute bronchitis, skin and soft‑tissue infections, and animal bites, offering a strong therapeutic option when lower strengths such as Augmentin 500mg may be insufficient.
The 875mg strength is primarily available as standard tablets, with capsule forms used less frequently. It is intended for adults and adolescents who require intensified antimicrobial exposure, particularly in moderate‑to‑severe presentations or infections with higher relapse risk. Compared with 500mg, the 875mg dose provides greater antibacterial activity, while differing from Augmentin XR, which is reserved mainly for recurrent or persistent sinusitis. Pediatric dosing guidance is available in the Pediatric section, and structured notes on GI tolerance, hypersensitivity, and drug interactions are outlined on the Side Effects and Interactions pages.
Augmentin 875mg is a high‑dose combination antibiotic containing amoxicillin and clavulanate, formulated to deliver enhanced beta‑lactam activity against resistant or deep‑seated bacterial pathogens. The clavulanate component protects amoxicillin from enzymatic degradation, allowing the drug to maintain reliable coverage across respiratory, ENT, dental, skin, and bite‑related infections. This strength is widely used in outpatient care for severe presentations of sinusitis, pneumonia, acute bronchitis, and complicated skin and soft‑tissue infections, offering a more potent alternative when lower doses may not provide sufficient therapeutic effect. A broader overview of the medication is available in the Augmentin overview.
Clinically, Augmentin 875mg is primarily prescribed to adults and adolescents who require intensified antimicrobial exposure due to infection severity, relapse risk, or pathogen profile. Its pharmacological design supports robust penetration into inflamed tissues, making it suitable for managing infections with higher bacterial loads or partial treatment response. The dosage is most commonly supplied as oral tablets, with capsule formulations used less frequently depending on regional availability and patient preference.
Overall, Augmentin 875mg represents a high‑strength therapeutic option within the amoxicillin–clavulanate family, balancing broad-spectrum coverage with enhanced stability against beta‑lactamase–producing organisms. Its established role in treating severe community‑acquired infections underscores its importance in modern antimicrobial practice, particularly for adult and adolescent patients requiring reliable, high‑dose oral therapy.
Augmentin 875mg is primarily manufactured as high‑strength oral tablets designed for adults and adolescents requiring intensified antimicrobial exposure. These tablets provide a stable ratio of amoxicillin and clavulanate, ensuring reliable absorption and predictable pharmacokinetics in severe respiratory, ENT, and skin infections. Detailed characteristics of the tablet formulation are available in the Tablets section.
Capsule forms of Augmentin 875mg exist but are used far less frequently and may not be available in all regions. Capsules offer similar therapeutic performance but are typically reserved for specific prescribing environments or patient preferences. Additional notes on capsule availability and structure can be found in the Capsules section.
Importantly, Augmentin 875mg is not produced as an oral suspension. Pediatric and weight‑based dosing relies on lower‑strength suspensions, allowing precise mg/kg calculations and safer administration for children. Because of this, the 875mg strength remains exclusively an adult and adolescent dosage form, optimized for high‑dose oral therapy in severe community‑acquired infections.
Augmentin 875mg is typically prescribed at a standard regimen of 875mg twice daily, providing high‑strength beta‑lactam coverage suitable for severe respiratory, ENT, dental, and skin infections. This dosing frequency ensures sustained serum concentrations of amoxicillin and clavulanate, supporting effective penetration into inflamed tissues and reliable activity against beta‑lactamase–producing organisms.
In cases of recurrent or persistent bacterial sinusitis, clinicians may transition patients to the extended‑release formulation, Augmentin XR, which maintains prolonged therapeutic levels and is specifically designed for difficult sinus infections. For most other severe infections, however, the standard 875mg twice‑daily regimen remains the preferred high‑dose option.
| Strength | Frequency | Use |
|---|---|---|
| 500mg | 2–3×/day | Moderate infections |
| 875mg | 2×/day | Severe infections |
| XR | 2×/day | Recurrent sinusitis |
Overall, the 875mg strength provides a balance of potency and convenience, making it one of the most commonly used high‑dose oral regimens in outpatient antimicrobial therapy for adults and adolescents.
Augmentin 875mg is not prescribed directly to children, as this high‑strength tablet formulation exceeds safe pediatric dosing thresholds. Instead, clinicians rely on weight‑based mg/kg calculations using pediatric‑appropriate suspensions, which allow precise titration of amoxicillin and clavulanate according to age, weight, and infection severity. This approach ensures both safety and therapeutic accuracy in infants and children.
Pediatric dosing strategies typically use lower‑strength suspensions to achieve daily totals aligned with standard guidelines for respiratory, ENT, and skin infections. These formulations provide flexible administration and improved tolerability, making them suitable for a wide range of pediatric clinical scenarios. Detailed pediatric guidance is available in the Pediatric section.
Because of these considerations, the 875mg strength remains exclusively an adult and adolescent option, while pediatric therapy continues to rely on carefully calculated mg/kg dosing through suspension formulations.
Augmentin 875mg is prescribed for severe community‑acquired infections where high‑dose amoxicillin–clavulanate is required to achieve adequate tissue penetration and beta‑lactamase coverage. One of the most common indications is acute bacterial sinusitis with marked inflammation, facial pressure, purulent discharge, or relapse after lower‑dose therapy. The enhanced clavulanate exposure helps counter resistant respiratory pathogens frequently involved in difficult sinus infections.
This strength is also widely used for community‑acquired pneumonia, especially when outpatient management is appropriate but pathogen load or symptom severity requires intensified oral therapy. In acute bronchitis, Augmentin 875mg is reserved for cases with suspected bacterial involvement, significant systemic symptoms, or failure of prior treatment.
Beyond respiratory infections, Augmentin 875mg is effective for complicated skin infections and soft‑tissue involvement, including cellulitis, abscesses, and infected wounds. It is also a first‑line option for animal bites, where polymicrobial flora and beta‑lactamase–producing organisms require broad, high‑strength coverage. Overall, the 875mg dose is positioned as a robust therapeutic choice for severe infections across respiratory, dermatologic, and bite‑related clinical scenarios.
Augmentin dosing varies significantly depending on infection severity and clinical presentation. The 500mg strength is typically used for moderate respiratory, ENT, and skin infections, providing sufficient amoxicillin–clavulanate exposure for routine outpatient cases. More details on this formulation are available in the Augmentin 500mg section.
The 875mg strength is reserved for severe infections requiring higher antibacterial activity, including difficult sinusitis, pneumonia, and complicated skin infections. Its increased amoxicillin load supports deeper tissue penetration and improved effectiveness against beta‑lactamase–producing organisms.
For recurrent or persistent sinusitis, clinicians may select the extended‑release formulation, Augmentin XR, which maintains prolonged serum concentrations and is specifically engineered for chronic or relapse‑prone sinus disease.
| Strength | Best Use | Notes |
|---|---|---|
| 500mg | Moderate infections | Standard adult dose |
| 875mg | Severe infections | High-strength |
| XR | Recurrent sinusitis | Extended release |
Together, these formulations provide a flexible dosing spectrum, allowing clinicians to tailor therapy precisely to infection severity, relapse risk, and patient‑specific needs.
Augmentin 875mg carries a well‑established safety profile, though its high clavulanate content increases the likelihood of gastrointestinal reactions. Patients frequently report nausea, abdominal discomfort, or loose stools, with diarrhea being more common at higher doses due to enhanced GI motility and microbiome disruption. A structured overview of typical reactions is available in the Augmentin side effects section.
Hypersensitivity reactions may occur in individuals with beta‑lactam allergies. Symptoms can include rash, pruritus, or more severe responses such as anaphylaxis. Patients with known penicillin allergies should review detailed guidance in the Penicillin allergy section before initiating therapy.
Dermatologic reactions such as mild maculopapular rash may appear during treatment, particularly in patients with viral infections or prior beta‑lactam exposure. While most reactions are self‑limited, any progression of symptoms warrants clinical evaluation. Overall, Augmentin 875mg remains a safe and effective high‑dose option when used appropriately, with predictable side‑effect patterns and clear management strategies.
Augmentin 875mg may interact with several commonly used medications, requiring careful monitoring in specific clinical situations. One of the most notable interactions involves warfarin: co‑administration can potentiate anticoagulant effects by altering gut flora and vitamin K metabolism, potentially increasing INR. Patients receiving warfarin should be monitored more closely during therapy, with structured guidance available in the Augmentin interactions section.
Another clinically relevant interaction occurs with allopurinol. When used together, the likelihood of dermatologic reactions — particularly rash — may increase. Although not universally observed, clinicians typically exercise caution when co‑prescribing these medications, especially in patients with a history of drug‑related skin reactions.
Probenecid can significantly affect Augmentin pharmacokinetics by reducing renal tubular secretion of amoxicillin, leading to elevated and prolonged serum levels. This interaction may be used intentionally in certain therapeutic contexts but generally requires medical supervision to avoid excessive beta‑lactam exposure.
Proper storage of Augmentin 875mg ensures stability, potency, and safe administration. The 875mg strength is available exclusively as tablets, which should be kept at standard room temperature in a dry environment away from moisture and direct sunlight. These conditions help maintain structural integrity and prevent degradation of both amoxicillin and clavulanate components throughout their shelf life.
Unlike lower strengths, Augmentin 875mg is not produced as an oral suspension. Pediatric dosing relies on weight‑based mg/kg calculations using dedicated suspension formulations, which require refrigeration after reconstitution. Detailed guidance on suspension handling is available in the Suspension section.
Overall, adherence to proper storage recommendations ensures consistent therapeutic performance and minimizes the risk of reduced efficacy due to improper handling, making correct storage practices essential for safe outpatient use.